ZoBio has launched a DNA-encoded library (DEL) service aimed at exploratory drug discovery programs. The company positions its platform as distinct from transactional DEL screening approaches, which typically focus narrowly on hit generation.
ZoBio's service is designed to deliver hit matter that is biologically relevant and structurally characterized. The company emphasizes that its hits come with clear potential for progression into lead optimization.
The offering targets early-stage drug discovery, where identifying high-quality chemical starting points is critical. By integrating structural biology from the outset, ZoBio aims to reduce attrition later in development.
This launch expands the competitive landscape for DEL services, which are increasingly used in pharmaceutical R&D. ZoBio's emphasis on structure-enabled hits could appeal to biotechs and academic groups seeking more translatable starting points.
The service is available immediately, though no pricing details or early access partners have been disclosed. Further validation will depend on case studies demonstrating the platform's performance in real discovery programs.